Bazedoxifene/conjugated estrogens
| Combination of | |
|---|---|
| Bazedoxifene | Selective estrogen receptor modulator |
| Conjugated estrogens | Conjugated estrogens |
| Clinical data | |
| Trade names | Duavee |
| Legal status |
|
| Routes of administration | Oral |
| Identifiers | |
| ATC code | G03CC07 |
| ChemSpider | none |
The drug combination bazedoxifene/conjugated estrogens (trade name Duavee in the US) is a medication approved by the Food and Drug Administration (FDA) for the treatment of menopause symptoms and postmenopausal osteoporosis. It is a fixed-dose combination drug containing the selective estrogen receptor modulator bazedoxifene and conjugated estrogens being marketed by the pharmaceutical company Pfizer.
Duavee was approved by the US FDA on October 3, 2013, for use as a once-daily tablet. Pfizer expects the drug to become available in the first quarter of 2014.[1]
References
This article is issued from Wikipedia - version of the Monday, January 04, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.